The primary objective of this protocol is to provide access to SU011248 treatment for patients with metastatic RCC who are ineligible for participation in ongoing SU011248 clinical studies and have the potential to derive clinical benefit from treatment with SU011248 based on the judgment of the investigator.
Given that an Expanded Access study does not meet the definition of a controlled clinical investigation, and as such, is not considered an applicable drug clinical trial per NIH, Basic Results for such studies are not required to be reported. Protocol A6181037 has been identified as an Expanded Access trial, and has been registered to ClinicalTrials.gov, however Basic Results will not be posted.
Drug: Sutent
Sutent, 25, 37.5. or 50 mg daily
Inclusion Criteria:
- renal cell carcinoma that is not amendable to standard therapy with curative intent
Exclusion Criteria:
- current treatment in another therapeutic clinical trial
Pfizer Investigational Site
Scottsdale, Arizona, 85260
Pfizer Investigational Site
San Francisco, California, 94115-2378
Pfizer Investigational Site
San Francisco, California, 94115
Pfizer Investigational Site
Aurora, Colorado, 80040-0510
Pfizer Investigational Site
Norwalk, Connecticut, 06856
Pfizer Investigational Site
Miami, Florida, 33176
Pfizer Investigational Site
Ocala, Florida, 34474
Pfizer Investigational Site
Tampa, Florida, 33612
Pfizer Investigational Site
Atlanta, Georgia, 30309
Pfizer Investigational Site
Maywood, Illinois, 60153
Pfizer Investigational Site
Indianapolis, Indiana, 46260-2082
Pfizer Investigational Site
Council Bluffs, Iowa, 51503
Pfizer Investigational Site
Covington, Louisiana, 70433
Pfizer Investigational Site
Gretna, Louisiana, 70056
Pfizer Investigational Site
Marrero, Louisiana, 70072
Pfizer Investigational Site
Metairie, Louisiana, 70002
Pfizer Investigational Site
Metairie, Louisiana, 70006
Pfizer Investigational Site
New Orleans, Louisiana, 70115
Pfizer Investigational Site
Baltimore, Maryland, 21287
Pfizer Investigational Site
Boston, Massachusetts, 02114
Pfizer Investigational Site
Boston, Massachusetts, 02115
Pfizer Investigational Site
Boston, Massachusetts, 02215
Pfizer Investigational Site
Detroit, Michigan, 48201
Pfizer Investigational Site
Minneapolis, Minnesota, 55455
Pfizer Investigational Site
Southaven, Mississippi, 38671
Pfizer Investigational Site
Tupelo, Mississippi, 38801
Pfizer Investigational Site
Columbia, Missouri, 65201
Pfizer Investigational Site
Columbia, Missouri, 65203
Pfizer Investigational Site
Omaha, Nebraska, 68198-7680
Pfizer Investigational Site
Bronx, New York, 10466
Pfizer Investigational Site
New York, New York, 10021
Pfizer Investigational Site
New York, New York, 10022
Pfizer Investigational Site
Durham, North Carolina, 27710
Pfizer Investigational Site
Cleveland, Ohio, 44195
Pfizer Investigational Site
Norman, Oklahoma, 73071
Pfizer Investigational Site
Oklahoma City, Oklahoma, 73102
Pfizer Investigational Site
Oklahoma City, Oklahoma, 73109
Pfizer Investigational Site
Oklahoma City, Oklahoma, 73112
Pfizer Investigational Site
Oklahoma City, Oklahoma, 73120
Pfizer Investigational Site
Tulsa, Oklahoma, 74104
Pfizer Investigational Site
Tulsa, Oklahoma, 74136-1902
Pfizer Investigational Site
Portland, Oregon, 97210
Pfizer Investigational Site
Portland, Oregon, 97227
Pfizer Investigational Site
Hershey, Pennsylvania, 17033-0850
Pfizer Investigational Site
Memphis, Tennessee, 38104
Pfizer Investigational Site
Memphis, Tennessee, 38120
Pfizer Investigational Site
Dallas, Texas, 75246
Pfizer Investigational Site
Salt Lake City, Utah, 84112
Pfizer Investigational Site
Seattle, Washington, 98104
Pfizer Investigational Site
Seattle, Washington, 98109
Pfizer Investigational Site
Seattle, Washington, 98122
Pfizer Investigational Site
Seattle, Washington, 98124
Pfizer Investigational Site
Madison, Wisconsin, 53792
Pfizer CT.gov Call Center
Study Director
Pfizer